Adage Capital Partners
XLO icon

Adage Capital Partners’s Xilio Therapeutics XLO Stock Holding History

Adage Capital Partners’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
+111,541
New +$932K ﹤0.01% 895

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Adage Capital Partners's XLO Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 111,541 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings.

24 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Adage Capital Partners held 111,541 shares of Xilio Therapeutics worth $1.07M as of Q2 2026.
  • Xilio Therapeutics was a new Adage Capital Partners position in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #895 holding.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.